Acceptability of cell substrates for production of biologicals : report of a WHO study group, meeting held in Geneva from 18 to 19 November 1986
Material type:
- 9241207477
- 100 SD:610.621 WHO.TR(747)
Item type | Current library | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|
Reports | ISI Library, Kolkata Reports & Records Collection | 100 SD:610.621 WHO.TR(747) (Browse shelf(Opens below)) | Available | C21572 |
Browsing ISI Library, Kolkata shelves, Shelving location: Reports & Records Collection Close shelf browser (Hides shelf browser)
No cover image available | No cover image available | |||||||
100 SD:610.621 WHO.TR.97 Joint FAO/WHO Expert Committee on Nutrition : fourth report | 100 SD:610.621 WHO.TR(343) WHO expert committee on dependence-producing drugs: fifteenth report/ | 100 SD:610.621 WHO.TR(344) Immunotherapy of cancer/ | 100 SD:610.621 WHO.TR(747) Acceptability of cell substrates for production of biologicals : report of a WHO study group, meeting held in Geneva from 18 to 19 November 1986 | 100 SD:610.621 WHO.TR(748) WHO Expert Committee on Specifications for Pharmaceutical Preparations : thirtieth report, meeting held in Geneva from 2 to 6 December 1985 | 100 SD:610.621 WHO.TR(749) Prevention and control of intestinal parasitic infections : report of a WHO Expert Committee, meeting held in Geneva from 3 to 7 March 1986 | 100 SD:610.621 WHO.TR(750) Alternative systems of oral care delivery : report of a WHO expert committee, meeting held in Geneva from 28 November to 4 December 1985 |
1. Background and introduction -- 2. Issues considered by the Study Group -- 3. Discussion and conclusions -- 4. Recommendations -- 5. Acknowledgements -- Annexes
A brief yet highly significant analysis of issues associated with the use of eukaryotic and prokaryotic cells in the production of biologicals. The report considers two main types of issues: first, the acceptability of developing a biological product in a new cell system when the same generic product is already being manufactured by an approved method, and second, the degree of risk associated with certain classes of possible contaminants in the product. These include heterogeneous contaminating DNA, viruses, and transforming poteins. For each contaminant, the report describes and analyses the potential risks to humans and, where appropriate, categorizes and classifies these risks. The report also advocates basic principles of manufacturing and testing that can help minimize the likelihood of risks to human recipients of products manufactured in continuous cell lines.
There are no comments on this title.